Magnitude Biosciences secures £1.3m to scale breakthrough drug discovery platform
Magnitude Biosciences, a specialist contract research organisation (CRO) and Durham University spinout, has secured £1.3m in funding to accelerate the commercialisation of VivoScanTM, its pioneering in vivo high-throughput screening (HTS) platform, which provides pharmaceutical and biotechnology companies with faster and more cost-effective ways to identify promising new treatments for ageing, longevity and neurodegenerative diseases. VivoScanTM […]
Nanovery secures over £1.85 million for cancer diagnostic solution
A Newcastle-based company has raised over £ 1.85 million of funding to help its quest to save more lives through better testing for prostate cancer. The funding includes £500,000 investment from the North East Innovation Fund, supported by the European Regional Development Fund and managed by Northstar Ventures alongside investment from Prostate Cancer Research together […]